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Incubation of neuroblastoma NIE 115 cells with veratrine leads to an apparent reduction in the number of 
muscarinic acetylcholine receptors assayed by [3H]scopolamine methyl chloride binding. No true down- 
regulation of the receptors occurs but a component of veratrine with muscarinic receptor affinity, which is 
not veratridine, enters the intracellular water space during the incubation period and competes with 
[3H]scopolamine methyl chloride for the muscarinic binding sites in subsequent ligand binding assays 
unless it is carefully washed away. Treatment of cells with the agonist carbamoylcholine does, however, 
lead to a true downregulation of muscarinic receptors. 
Muscarinic receptor Neuroblastoma cell Veratridine Veratrine 
1. INTRODUCTION 
The alkaloid toxin veratridine is a lipid-soluble 
polycyclic compound which depolarizes excitable 
cells by causing persistent sodium channel activa- 
tion [ 11. Veratrine, a commercially available prod- 
uct containing a mixture of Verutrum alkaloids has 
been used as a source of veratridine [2,3] and has 
been reported to cause a loss of muscarinic acetyl- 
choline receptor sites in synaptosomes from rat 
cerebral cortex 121. This veratrine-stimulated loss 
of muscarinic receptor sites could be prevented by 
the inclusion of tetrodotoxin in the incubation me- 
dium. The adrenergic neuroblastoma clone NlE 
115 [4] has been widely used to study aspects of 
neuronal function [5-71 and is known to possess 
inhibitory muscarinic receptors [8]. Here we pre- 
sent results showing that an apparent loss of mus- 
carinic receptor binding sites in cells of NlE 115 
induced by veratrine is due to a component of ve- 
ratrine possessing muscarinic receptor antagonist 
activity. 
tetrodotoxin and atropine sulphate were obtained 
from Sigma (London) Chemicals (Poole). All other 
chemicals were of the highest purity available and 
were obtained from commercial sources. 
[3H]NMS binding to a broken cell preparation 
of N 1E 115 was assayed by a rapid filtration 
method. 13HlNM.S (- 500 PM) was incubated with 
the broken cell preparation (0.5 mg protein/ml) at 
25°C for 60 min with the addition of competing 
drugs where appropriate in 1 ml final vol. of a 
Hepes-phosphate-saline buffer (pH 7.4) [9]. In- 
cubation was terminated by addition of 2 ml ice- 
cold buffer and the mixture was filtered rapidly 
under reduced pressure through a Whatman GF/ 
B glass fibre filter presoaked in buffer. The filter 
was then quickly washed with 3 portions (2 ml) of 
ice-cold buffer and transferred to 3 ml Fisofluor I 
scintillant (Fisons Ltd., Loughborough) containing 
0.2 ml water for determination of bound radioac- 
tivity. Specific [3H]NMS binding was defined as 
that displaceable by 20 PM ( f )atropine and under 
these conditions the specific binding was - 70% of 
the total binding. 
2. MATERIALS AND METHODS 
[3H]Scopolamine methyl chloride ([3H]NMS) 
(53.5 Ci/mmol) was obtained from New England 
Nuclear (Southampton). Veratrine, veratridine, 
N 1E 115 cells (P 20-30) were grown in the tissue 
culture in Dulbecco’s modified Eagle’s medium 
supplemented with 5% (v/v) foetal calf serum 
(Gibco Biocult, Paisley) without antibiotics at 
37°C in a humidified atmosphere containing 10% 
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CO2. The medium was changed on days 3,5 and 6 
after subculture and the cells harvested on day 7. 
The effect of veratrine on muscarinic receptor 
binding site number was assessed by adding 8 ml 
of veratrine solution (100-500 PM) to plates 
(55 cm2) of NlE 115 cells from which the medium 
had been removed and the cell monolayer washed 
with 2 x 5 ml portions of buffer. (The concentra- 
tion of the veratrine solution was calculated 
assuming an av. M, = 600 for veratrine. Such an 
assumption is necessary in order to enable experi- 
ments with veratrine to be carried out quantitative- 
ly and in order to estimate the affinity of any com- 
ponent of veratrine for muscarinic receptors. The 
actual M,-value of any receptor-active substance is 
unimportant for the determination of pseudo Hill 
coefficients from displacement binding curves.) 
The plates were then incubated for 6 h at 37°C. 
Incubation was terminated by removal of the in- 
cubation medium and washing the cell monolayer 
with 3 x 5 ml portions of ice-cold buffer before 
the cells were removed mechanically from the 
plate using a stream of buffer (total vol. 2 ml) and 
frozen at -80°C until the muscarinic binding sites 
were assayed. Studies on agonist-mediated down- 
regulation were performed as above except that 
carbamoylcholine (1 mM) replaced veratrine. A 
modified procedure including extended washing 
was adopted in some experiments (fig.3). 
3. RESULTS AND DISCUSSION 
In initial experiments, incubation of plates of 
NlE 115 with veratrine (100-500 PM) for 6 h fol- 
lowed by washing of the plates with 3 x 5 ml por- 
tions of buffer led to a concentration-dependent 
reduction of specific [3H]NMS binding to broken 
cell preparations in comparison to those which had 
been incubated without veratrine (not shown), in 
agreement with 121. However, the loss of specific 
binding of [3H]NMS was not prevented by inclu- 
sion of the sodium channel blocker tetrodotoxin at 
concentrations up to 20 PM in the incubation me- 
dium (fig.l). This indicates that the observed re- 
duction of specific 13H]NMS binding after treat- 
ment of the cells with veratrine was not caused by 
a depolarization of the plasma membrane medi- 
ated by veratridine. 
When veratrine at varying concentrations was 
added to a muscarinic receptor binding assay of a 
40 
broken cell preparation which had not been ex- 
posed to veratrine previously, specific [3H]NMS 
binding was completely displaced with an ICsu 
(concentration of substance giving 50% inhibition 
of binding) of 0.32 PM (corrected for receptor oc- 
cupancy) (fig.2) the displacement having a pseudo 
Hill coefficient of 0.93. This value for the corrected 
ICsu of the receptor-active component of veratrine 
must necessarily be only an estimate of the true 
value owing to the assumed M,-value of veratrine, 
but this assumption does not affect the value of the 
pseudo Hill coefficient obtained. For brain mus- 
carinic receptors, classical muscarinic antagonists 
produce pseudo Hill coefficients close to 1.0 while 
muscarinic agonists produce pseudo Hill coeffi- 
cients significantly less than 1.0 [l 11. These data 
suggest, therefore, that the component of veratrine 
which interacts with muscarinic receptors may be 
an antagonist. The inhibition of [3H]NMS binding 
is competitive as shown by saturation binding 
analyses performed in the presence and absence of 
veratrine (in preparation). Veratridine (90-95s) 
was unable to displace > 18% of the specific 
[3H]NMS binding at up to 100 PM so that the 
receptor-active component of veratrine is not 
veratridine. Because of the ability of veratrine to 
displace [3H]NMS binding we examined the pos- 
sibility that the observed reduction in binding in 
N 1E 115 upon chronic exposure was related to the 
washing procedure or to the uptake into the cells 
during the incubation of a component of veratrine 
which inhibits muscarinic receptor binding. Using 
an extended washing procedure (lig.3) we have 
shown that this is indeed the case. In a typical ex- 
periment pellets P2 and P3 (extensively washed 
membrane fractions) gave 102.3% and 107.7%, re- 
spectively, of the control specific binding in com- 
parison to 5 1.7% observed without the extended 
washing procedures (table 1). That the extracellu- 
lar fluid after the standard washing procedure (S1 
supernatant) still contained a component capable 
of displacing specific [3H]NMS binding was shown 
by the fact that the standard veratrine incubation 
showed reduced specific binding in comparison to 
a veratrine incubation in which the S1 supernatant 
was removed and replaced with fresh buffer prior 
to freezing the cells (PI). The St supernatant also 
inhibited specific [jH]NMS binding when added to 
broken cell preparations which had not previously 
been exposed to veratrine (table I). The SZ super- 
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Fig. 1. The effect of tetrodotoxin on the veratrine-induced loss of specific [3H]NMS binding in broken cell preparations 
of NlE 115. Plates of N IE 115 were incubated for 6 h at 37°C in the presence of 300 PM veratrine and increasing 
concentrations of tetrodotoxin. Cells were harvested and prepared as described and the binding of [3H]NMS 
( - 500 PM) was determined. Each point is the mean of quadruplicate assays. IOOS binding is that observed in incuba- 
tions in the absence of veratrine. 
natant, which was derived from intracellular fluid 
(fig.3), was also able to inhibit specific [3H]NMS 
binding to control broken cell preparations and the 
S3 supematant (equivalent to St + S2) inhibited 
specific binding of [3H]NMS to an extent equiv- 
oyy--$-+ L -4 
log [veratrine] (M) 
Fig.2. Displacement of specific 13H]NMS (500 PM) 
binding by veratrine. Increasing concentrations of ve- 
ratrine were included in the standard assay and points 
were determined in quadruplicate. An av. M, = 600 was 
assumed for veratrine (see text). 
Table 1 
Veratrine treatment and muscarinic acetylcholine 
receptor binding in N IE 115 cells 
Condition Standard Extended washing procedure 
procedure P, 
p2 p3 
Veratrine-treated cells 
% control 
binding 51.7 77.8 102.3 107.7 
Condition + SI + s2 + s3 (sI+sz) 
Untreated cells 
9;; control 
binding 64.3 61.4 52.5 49.0 
Cells were treated with veratrine (300 PM, 37°C 6 h) 
using the standard procedure or the extended washing 
procedure (tig.3) and muscarinic receptors assayed as 
described (0.5 mg protein/assay). In addition superna- 
tant fractions (St, S2, S3) (volume equivalent to 0.5 mg 
protein from the fraction from which it was isolated) 
were added to membrane fragments from cells pre- 
viously untreated with veratrine and muscarinic recep- 
tors assayed. The results are from a typical experiment 
each point being determined in quadruplicate 
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cells washed 3 times with 
5ml buffer 
cells collected 
centrifugation 
(lOOg, 5 mins.) 
I? 
Pellet resuspended 
by cells broken by 
freezing (-80°C) 
and collected by 
centrifugation 
(12OOOg, 1 min.) 
Supernatant 
sl 
in 
original volume of 
buffer and frozen 
to break cells (P ) 
and then collecte A 
by centrifugation 
(12OOOg, 1 min.) 
-Supernatant 
1 
s3 
Pellet resuspended in 
original volume of 
buffer and collected 
by centrifugation 
(12OOOg, 1 min.) 
I 
IL Supernatant 
s2 
I 
Pellet resuspended in 
original volume of 
buffer and collected 
by centrifugation 
(12OOOg, 1 min.) 
Pellet resuspended in 
original volume of 
buffer (P3) 
Supernatant 
discarded 
\lr 
Pellet resuspended in 
original volume of 
buffer (P2) 
Fig.3. Extended washing procedure for removal of veratrine associated with cells. 
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Table 2 
Carbamoylcholine treatment and muscarinic acetyl- 
choline receptor binding in N 1E 115 cells 
Condition Standard Extended washing procedure 
procedure PI p2 
8 control 
Carbamoylcholine-treated cells 
binding 41.4 39.9 57.4 
Condition + SI + s2 + s3 
% control 
Untreated cells 
binding 95.4 84.4 80.0 
Cells were treated with carbamoylcholine (1 mM, 37°C 
6 h) using the standard procedure or the extended wash- 
ing procedure (tig.3) and muscarinic receptors assayed 
as described (0.5 mg protein/assay). In addition super- 
natant fractions (St, S2, S3) (volume equivalent to 
0.5 mg protein from the fraction from which it was iso- 
lated) were added to membrane fragments from cells 
previously untreated with carbamoylcholine and mus- 
carinic receptors assayed. The results are from a typical 
experiment each point being determined in 
quadruplicate 
alent to that expected for the combined superna- 
tants St and $ (table 1). 
As a comparison we examined whether agonist- 
stimulated downregulation of muscarinic receptor 
binding sites would be affected by the extended 
washing procedure. N 1E 115 cells were incubated 
for 6 h with carbamoylcholine (1 mM) (table 2). 
The carbamoylcholine treated cells showed 4 1.4% 
of the specific 13H]NMS binding of control incuba- 
tions and the extended washing procedure in- 
creased this to 57.4% of control binding. Addition 
of the S) supernatant to cells previously untreated 
with carbamoylcholine had little effect on binding 
but supernatants S2 and S3 both reduced specific 
[JH]NMS binding by 15-20’3 suggesting that over 
the incubation period a small amount of car- 
bamoylcholine enters or becomes associated with 
the cells. 
These results show that veratrine contains a 
component whose actions are consistent with it 
being a muscarinic antagonist and that veratrine 
produces no true loss of muscarinic receptor bind- 
ing sites in cells of N 1E 115 grown in tissue culture 
while the cholinergic agonist carbamoylcholine 
stimulates a true loss of binding sites. 
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